Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system
US10280419B2 · kind B2 · utility
1Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2015 |
| Grant date | May 7, 2019 |
| Priority date | — |
| Expiry date | May 8, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and products are described related to use of the CRISPR/Cas9 system to introduce a modification into an APP gene, such as guide RNAs and recombinant proteins, for decreasing amyloid beta peptide produced by a cell. Also described are uses of such methods and products for the treatment of Alzheimer's disease and/or age-related cognitive decline in a cell from a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.